LIRAGLUTIDE AND WEIGHT LOSS AMONG PATIENTS WITH ADVANCED HEART FAILURE AND A REDUCED EJECTION FRACTION: INSIGHTS FROM THE FIGHT TRIAL

Background: More than 50% of patients with heart failure (HF) and a reduced ejection fraction (EF) are overweight. Although liraglutide is FDA-approved for weight loss, prior clinical trials excluded patients with HF. Methods: Patients with a recent hospitalization for HF and an EF